625375-84-0|Tariquidar dimesylate|N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide dimesylate|-范德生物科技公司

Tariquidar dimesylate

NMR下载 COA and HPLC MSDS下载
names：
N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide dimesylate
CAS号：
625375-84-0
MDL Number：
MF(分子式)： C40H46N4O12S2 MW(分子量)： 838.94
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide dimesylate
英文别名	Tariquidar dimesylate; Tariquidar dimesilate; XR 9576, XR9576, XR-9576, D06008, D 06008, D-06008,
CAS号	625375-84-0
SMILES	O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O.OS(=O)(C)=O.OS(=O)(C)=O
Inchi	InChI=1S/C38H38N4O6.2CH4O3S/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27;21-5(2,3)4/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43);21H3,(H,2,3,4)
InchiKey	FBCFBFPCZHHRMA-UHFFFAOYSA-N
分子式 Formula	C40H46N4O12S2
分子量 Molecular Weight	838.94
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tariquidar dimesylate(CAS:625375-84-0 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tariquidar, also known as XR9576, is a P-glycoprotein (P-gp) inhibitor undergoing research as an adjuvant against multidrug resistance in cancer. Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs. Inhibition of transmembrane transport may result in increased intracellular concentrations of an anticancer drug, thereby augmenting its cytotoxicity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Joshi P, Vishwakarma RA, Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017 Sep 29;138:273-292. doi: 10.1016/j.ejmech.2017.06.047. Epub 2017 Jun 27. Review. PubMed PMID: 28675836.

[2]Lubberink M. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography. Curr Pharm Des. 2016;22(38):5786-5792. Review. PubMed PMID: 27494063.

[3] Zinzi L, Capparelli E, Cantore M, Contino M, Leopoldo M, Colabufo NA. Small and Innovative Molecules as New Strategy to Revert MDR. Front Oncol. 2014 Jan 21;

[4]2. doi: 10.3389/fonc.2014.00002. eCollection 2014. Review. PubMed PMID: 24478983; PubMed Central PMCID: PMC3896858.

[5] Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):68-77. doi: 10.1002/jlcr.2993. Review. PubMed PMID: 24285312.

5: Lecerf-Schmidt F, Peres B, Valdameri G, Gauthier C, Winter E, Payen L, Di Pietro A, Boumendjel A. ABCG

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开